Comparative Pharmacology
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 1 80 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO CYCLEN 21 versus ORTHO NOVUM 1 80 21.
ORTHO CYCLEN-21 vs ORTHO-NOVUM 1/80 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norgestimate. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release from pituitary, inhibiting ovulation. Increases viscosity of cervical mucus, impeding sperm penetration. Induces endometrial thinning, reducing implantation likelihood.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg for days 1-7, norgestimate 0.215 mg/ethinyl estradiol 0.035 mg for days 8-14, norgestimate 0.250 mg/ethinyl estradiol 0.035 mg for days 15-21) orally once daily for 21 days, followed by 7 placebo tablets (if included) or 7 drug-free days, then repeat.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Terminal elimination half-life: Norgestimate metabolite (norelgestromin) ~28 hours; Ethinyl estradiol ~17 hours (range 13-27 hours). Clinical context: Steady-state achieved within 10-14 days.
Norethindrone terminal half-life: 8-11 hours; Mestranol (ethinyl estradiol pro-drug) terminal half-life: 10-15 hours (metabolite ethinyl estradiol). Clinical context: Steady-state reached in 5-7 days; once-daily dosing maintains therapeutic levels.
Approximately 40% renal (as metabolites), 60% biliary/fecal (as metabolites). Norgestimate metabolites are excreted primarily in urine (40-50%) and feces (50-60%). Ethinyl estradiol metabolites are excreted in urine (40%) and feces (60%).
Renal: ~60% (metabolites, primarily glucuronide and sulfate conjugates), Fecal: ~40% (biliary excretion of metabolites). Unchanged drug negligible.
Category C
Category C
Hormonal Contraceptive
Hormonal Contraceptive